Gaiz Almottesembellah Abdalruhman, Mosawy Sapha, Colson Natalie, Singh Indu
Altern Ther Health Med. 2018 May;24(3):40-47.
Context • Type 2 diabetes mellitus is an independent precipitating factor for cardiovascular disease (CVD). Heart disease is one of the leading causes of mortality in patients with diabetes, mainly due to macrovascular complications, such as atherosclerosis. Although aspirin is a frequently used therapy for the inhibition of platelet hyperactivity, many studies suggest that aspirin resistance is rising. Objective • The study intended to investigate the benefits of anthocyanin (AC) as an antioxidant with inhibitory effects on platelets and, consequently, its potential usefulness as complementary antiplatelet therapy to attenuate the negative effects of atherosclerosis and CVD in patients with diabetes. Design • The research team performed a literature review. The team conducted a database search from 2007 to 2017 using Library of Congress, LISTA, PubMed, and Web of Science Core Collection databases, using the following keywords: anthocyanins, platelet, cardiovascular disease, and diabetes. Setting • The study took place at the School of Medical Sciences at Griffith University's Gold Coast campus (Southport, Australia). Results • Platelets have a major pathophysiological role of atherosclerosis and consequently CVD in diabetes. Antiplatelet drugs have a potent inhibitory effect of thrombotic and CVD risks in diabetes. Dietary antioxidants including ACs have a potential platelet inhibitory effect. Hence, ACs may act as complementary therapy to reduce CVD in diabetes. Conclusions • Although antiplatelet drugs such as aspirin provide significant action in the management of CVD, aspirin has limited benefits in diabetes. An AC antioxidant has a potential effect as an antiplatelet agent that subsequently can prevent atherosclerosis and CVD and, therefore, AC may be an alternative to other antiplatelet drugs such as aspirin. However, more interventional studies and large-scale clinical trials are necessary to prove the efficiency of AC as an alternative to other platelet-inhibitory drugs.
背景 • 2型糖尿病是心血管疾病（CVD）的一个独立促发因素。心脏病是糖尿病患者死亡的主要原因之一，主要是由于大血管并发症，如动脉粥样硬化。尽管阿司匹林是抑制血小板过度活跃常用的治疗方法，但许多研究表明阿司匹林抵抗现象正在增加。
目的 • 本研究旨在探讨花色苷（AC）作为一种对血小板有抑制作用的抗氧化剂的益处，以及因此其作为辅助抗血小板治疗以减轻糖尿病患者动脉粥样硬化和CVD负面影响的潜在用途。
设计 • 研究团队进行了文献综述。该团队使用美国国会图书馆、LISTA、PubMed和科学网核心合集数据库，通过以下关键词从2007年至2017年进行了数据库检索：花色苷、血小板、心血管疾病和糖尿病。
地点 • 该研究在格里菲斯大学黄金海岸校区（澳大利亚南港）医学科学学院进行。
结果 • 血小板在糖尿病患者的动脉粥样硬化以及由此导致的CVD中具有主要的病理生理作用。抗血小板药物对糖尿病患者的血栓形成和CVD风险有强大的抑制作用。包括花色苷在内的膳食抗氧化剂具有潜在的血小板抑制作用。因此，花色苷可能作为辅助治疗来降低糖尿病患者的CVD风险。
结论 • 尽管阿司匹林等抗血小板药物在CVD管理中发挥着重要作用，但阿司匹林对糖尿病患者的益处有限。AC抗氧化剂作为一种抗血小板药物具有潜在作用，随后可预防动脉粥样硬化和CVD，因此，AC可能是阿司匹林等其他抗血小板药物的替代品。然而，需要更多的干预性研究和大规模临床试验来证明AC作为其他血小板抑制药物替代品的有效性。
